Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 7/20 | 0.38 |
| ▸ | FAAH | O00519 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 4/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329202 | 0.93 | ALOX5 (0.39) | ALOX5FFAR4SLC13A5L3MBTL1POLB | |
| SCHEMBL16056930 | 0.79 | BID (0.44) | SLC13A5DAGLAFAAHALDH1A1GAA | |
| SCHEMBL16057371 | 0.78 | BID (0.47) | SLC13A5DAGLAFAAHALDH1A1GAA | |
| SCHEMBL14974628 | 0.76 | SLC13A5 (0.44) | SLC13A5L3MBTL1KMT2A | |
| SCHEMBL16678280 | 0.76 | PLCG1 (0.39) | FFAR4SLC13A5L3MBTL1 | |
| SCHEMBL16057405 | 0.76 | PTGER1 (0.46) | SLC13A5L3MBTL1DAGLAFAAHALDH1A1 | |
| SCHEMBL17556994 | 0.74 | FAAH (0.41) | ALOX5L3MBTL1FAAHKMT2A | |
| SCHEMBL17556996 | 0.74 | FAAH (0.41) | ALOX5L3MBTL1FAAHKMT2A | |
| SCHEMBL16058003 | 0.73 | ABCB1 (0.47) | SLC13A5L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL16058091 | 0.72 | SLC13A5 (0.42) | SLC13A5L3MBTL1POLBDAGLAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828338-B2 | Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-28 | — | — | US | disclosed |
| EP-2782567-B1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | UNIV CALIFORNIA (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160235707-A1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | FOND ST ITALIANO TECNOLOGIA (IT) | 2016-08-18 | — | — | US | disclosed |
| US-9353075-B2 | Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-10 | — | — | US | disclosed |
| EP-2782567-A1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | The Regents of The University of California (US) | 2014-10-01 | — | — | EP | disclosed |
| WO-2014144836-A2 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20130281490-A1 | Disubstituted Beta-lactones as Inhibitors of N-Acylethanolamine Acid Amidase (NAAA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-24 | — | — | US | disclosed |
| WO-2013078430-A1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | NAAA, FAAH, FAAH2 | ALOX5 163/4885FFAR4 234/4885SLC13A5 2298/4885 |
| US-20130281490-A1 | Disubstituted Beta-lactones as Inhibitors of N-Acylethanolamine Acid Amidase (NAAA) | NAAA, FAAH, FAAH2 | ALOX5 250/4885FFAR4 463/4885SLC13A5 3028/4885 |
| US-20160235707-A1 | DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) | NAAA, FAAH, FAAH2 | ALOX5 250/4885FFAR4 463/4885SLC13A5 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.